Display Settings:

Format

Send to:

Choose Destination
Cancer Res Treat. 2005 Oct;37(5):273-8. doi: 10.4143/crt.2005.37.5.273. Epub 2005 Oct 31.

Treatment outcomes of three-dimensional conformal radiotherapy for stage III non-small cell lung cancer.

Author information

  • 1Department of Radiation Oncology, Chungnam National University, Daejeon, Korea.

Abstract

PURPOSE:

To evaluate the treatment outcomes of the three-dimensional conformal radiotherapy (3D-CRT), in conjunction with induction chemotherapy, for the treatment of stage III non-small cell lung cancer (NSCLC).

MATERIALS AND METHODS:

Between November 1998 and March 2003, 22 patients with histologically proven, clinical stage III NSCLC, treated with induction chemotherapy, followed by 3D-CRT, were retrospectively analyzed. There were 21 males (96%) and 1 female (4%), with a median age of 68.5 (range, 42 approximately 79). The clinical cancer stages were IIIA and IIIB in 41 and 59%, respectively. The histologies were squamous cell carcinoma, adenocarcinoma and others in 73, 18 and 9%, respectively. Twenty patients (91%) received induction chemotherapy before radiation therapy. The majority of the chemotherapy regimen consisted of cisplatin and gemcitabine. Radiation was delivered with conventional anteroposterior/posteroanterior fields for 36 Gy, and then 3D-CRT was performed. The total radiation dose was 70.2 Gy. The median follow-up period was 17 months (range, 4~59 months).

RESULTS:

The median overall survival was 19 months. The two and four-year overall survival rates were 37.9 and 30.3%, respectively. The median progression-free survival was 21 months. The two and four-year progression-free survival rates were 42.1 and 21%, respectively. The prognostic factors for overall survival by a univariate analysis were age, histology and T stage (p<0.05). Acute radiation toxicities, as evaluated by the RTOG toxicity criteria, included two cases of grade 3 lung toxicity and one case of grade 2 esophagus toxicity.

CONCLUSION:

The radiation dose could be increased without a significant increment in the acute toxicities when using 3D-CRT. It also seems to be a safe, well-tolerated and effective treatment modality for stage III NSCLC.

KEYWORDS:

Chemoradiotherapy; Conformal radiotherapy; Non-small cell lung carcinoma

PMID:
19956526
[PubMed]
PMCID:
PMC2785930
Free PMC Article

Images from this publication.See all images (2)Free text

Fig. 1
Fig. 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Korean Cancer Association Icon for PubMed Central
    Loading ...
    Write to the Help Desk